Iambic Therapeutics closed a financing round exceeding $100 million with participation from ARK Invest and Regeneron, the San Diego biotech’s CEO told Endpoints. The cash infusion will accelerate multiple programs built on the company’s AI‑driven discovery platform as it advances preclinical and early clinical candidates. Investors highlighted the strategic value of pairing computational discovery with deep bench biology. Iambic said funds will be allocated toward IND‑enabling studies and expanding its discovery engine; the round signals continued investor appetite at the intersection of machine learning and biologics discovery.